December 19, 2024

Comparing CBT Delivery Methods in Atopic Dermatitis

A new study published in JAMA Dermatology reveals that a self-guided online cognitive behavioral therapy program for atopic dermatitis was noninferior to clinician-guided treatment, offering promise for disseminating evidence-based psychological treatment for patients.

Conexiant

December 16, 2024

FDA 6-Month Drug Pipeline

A pipeline of novel drugs awaits FDA review through the first half of 2025.

Conexiant

December 12, 2024

Phase 3 Data: Nemolizumab for Prurigo Nodularis Relief

A recent study published in JAMA Dermatology revealed the significant efficacy of nemolizumab in reducing pruritus and skin lesions in patients with moderate to severe prurigo nodularis.

Conexiant

December 09, 2024

Reduced Infection Rates with Long-Term Dupilumab in Kids

A recent study reveals that dupilumab can reduce infection rates in young children with moderate-to-severe atopic dermatitis, offering potential long-term benefits for this patient population.

Conexiant

November 26, 2024

Moisturizers in Dermatitis: Risk vs Reward

A recent review finds that moisturizers, commonly used in dermatitis care, may lead to adverse effects in children with eczema, emphasizing the need for moderation and personalized recommendations for their use. Published in the Journal of the American Academy of Dermatology.

Conexiant

May 28, 2024

Study Links Blood Pressure Meds to Eczema Risk in Seniors

Antihypertensive drugs linked to small increased risk of eczema in older adults, with diuretics and calcium channel blockers showing the highest risk, study finds.

Conexiant

June 03, 2024

New Topical Antipruritic Spray Shows Promise in Treating EGFR-Related Dermatitis

A new study reveals the efficacy of a topical antipruritic spray containing traditional Chinese medicine ingredients in treating EGFR-related dermatitis in cancer patients.

Conexiant

July 02, 2024

Black Docs Lacking Amid Growing Attacks on Diversity Programs

Research has shown that patients of color prefer seeing doctors of their own race — and some studies have shown health outcomes are better for Black patients seeing Black doctors.

KFF Health News

July 17, 2024

Cendakimab Shows Promise in Phase II Trial for Atopic Dermatitis

Discover the potential of cendakimab, an anti–interleukin-13 monoclonal antibody, to improve symptoms in adult patients with moderate to severe atopic dermatitis, as demonstrated in a recent phase II clinical trial published in JAMA Dermatology.

Conexiant